keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/28914118/universal-opt-out-screening-for-hepatitis-c-virus-hcv-within-correctional-facilities-is-an-effective-intervention-to-improve-public-health
#1
Meghan D Morris, Brandon Brown, Scott A Allen
Purpose Worldwide efforts to identify individuals infected with the hepatitis C virus (HCV) focus almost exclusively on community healthcare systems, thereby failing to reach high-risk populations and those with poor access to primary care. In the USA, community-based HCV testing policies and guidelines overlook correctional facilities, where HCV rates are believed to be as high as 40 percent. This is a missed opportunity: more than ten million Americans move through correctional facilities each year. Herein, the purpose of this paper is to examine HCV testing practices in the US correctional system, California and describe how universal opt-out HCV testing could expand early HCV detection, improve public health in correctional facilities and communities, and prove cost-effective over time...
September 11, 2017: International Journal of Prisoner Health
https://www.readbyqxmd.com/read/28910222/restricted-access-state-medicaid-coverage-of-sofosbuvir-hepatitis-c-treatment
#2
Marea B Tumber
Chronic hepatitis C (HCV) infection can persist for decades without symptoms. Many Americans are unaware of their infection status and are not receiving necessary care and treatment. This places them at greater risk for severe, even fatal, complications from the disease and increases the likelihood that they will transmit the virus to others. In late 2013, the Food and Drug Administration approved a direct acting antiviral drug called sofosbuvir to treat chronic HCV infection. Sofosbuvir is a highly effective, but very expensive, curative treatment for HCV...
January 2017: Journal of Legal Medicine
https://www.readbyqxmd.com/read/28903757/access-to-medicines-and-hepatitis-c-in-africa-can-tiered-pricing-and-voluntary-licencing-assure-universal-access-health-equity-and-fairness
#3
Yibeltal Assefa, Peter S Hill, Anar Ulikpan, Owain D Williams
BACKGROUND: The recent introduction of Direct Acting Antivirals (DAAs) for treating Hepatitis C Virus (HCV) can significantly assist in the world reaching the international target of elimination by 2030. Yet, the challenge facing many individuals and countries today lies with their ability to access these treatments due to their relatively high prices. Gilead Sciences applies differential pricing and licensing strategies arguing that this provides fairer and more equitable access to these life-saving medicines...
September 13, 2017: Globalization and Health
https://www.readbyqxmd.com/read/28893741/prevention-and-assessment-of-infectious-diseases-among-children-and-adult-migrants-arriving-to-the-european-union-european-economic-association-a-protocol-for-a-suite-of-systematic-reviews-for-public-health-and-health-systems
#4
Kevin Pottie, Alain D Mayhew, Rachael L Morton, Christina Greenaway, Elie A Akl, Prinon Rahman, Dominik Zenner, Manish Pareek, Peter Tugwell, Vivian Welch, Joerg Meerpohl, Pablo Alonso-Coello, Charles Hui, Beverley-Ann Biggs, Ana Requena-Méndez, Eric Agbata, Teymur Noori, Holger J Schünemann
INTRODUCTION: The European Centre for Disease Prevention and Control is developing evidence-based guidance for voluntary screening, treatment and vaccine prevention of infectious diseases for newly arriving migrants to the European Union/European Economic Area. The objective of this systematic review protocol is to guide the identification, appraisal and synthesis of the best available evidence on prevention and assessment of the following priority infectious diseases: tuberculosis, HIV, hepatitis B, hepatitis C, measles, mumps, rubella, diphtheria, tetanus, pertussis, poliomyelitis (polio), Haemophilus influenza disease, strongyloidiasis and schistosomiasis...
September 11, 2017: BMJ Open
https://www.readbyqxmd.com/read/28881157/identifying-cost-effective-screening-algorithms-for-active-hepatitis-c-virus-infections-in-a-high-prevalence-setting
#5
Paul Jülicher, Claudio Galli
OBJECTIVE: To evaluate the cost-effectiveness of different screening patterns for active chronic hepatitis C virus (HCV) infections utilizing the hepatitis C core antigen test compared to standard care in the context of a general screening program in a high-prevalence country. METHODS: This study developed a decision analytic model to estimate the cost-effectiveness of four screening algorithms for the detection of active HCV infections among asymptomatic individuals with an unknown HCV status in a context of high (>5%) HCV prevalence...
September 7, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28877190/regional-differences-in-treatment-rates-for-patients-with-chronic-hepatitis-c-infection-systematic-review-and-meta-analysis
#6
Philip Vutien, Michelle Jin, Michael H Le, Pauline Nguyen, Sam Trinh, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang, Mindie H Nguyen
BACKGROUND & AIMS: Treatment rates with interferon-based therapies for chronic hepatitis C have been low. Our aim was to perform a systematic review of available data to estimate the rates and barriers for antiviral therapy for chronic hepatitis C. METHODS: We conducted a systematic review and meta-analysis searching MEDLINE, SCOPUS through March 2016 and abstracts from recent major liver meetings for primary literature with available hepatitis C treatment rates...
2017: PloS One
https://www.readbyqxmd.com/read/28877177/an-in-vitro-diagnostic-certified-point-of-care-single-nucleotide-test-for-il28b-polymorphisms
#7
Darragh Duffy, Estelle Mottez, Shaun Ainsworth, Tan-Phuc Buivan, Aurelie Baudin, Muriel Vray, Ben Reed, Arnaud Fontanet, Alexandra Rohel, Ventzislava Petrov-Sanchez, Laurent Abel, Ioannis Theodorou, Gino Miele, Stanislas Pol, Matthew L Albert
Numerous genetic polymorphisms have been identified as associated with disease or treatment outcome, but the routine implementation of genotyping into actionable medical care remains limited. Point-of-care (PoC) technologies enable rapid and real-time treatment decisions, with great potential for extending molecular diagnostic approaches to settings with limited medical infrastructure (e.g., CLIA certified diagnostic laboratories). With respect to resource-limited settings, there is a need for simple devices to implement biomarker guided treatment strategies...
2017: PloS One
https://www.readbyqxmd.com/read/28860020/triplex-hrm-assay-for-the-simultaneous-assessment-of-il28b-rs12979860-abcb11-rs2287622-and-rnf7-rs16851720-genotypes-in-chronic-hepatitis-c-patients
#8
Elena Luminita Enache, Anca Sin, Liviu Sorin Enache, Ligia Bancu
Chronic hepatitis C (CHC) is a leading cause of liver disease. Despite the improved efficacy of new antivirals, their high costs preclude their adoption in resource-limited settings, where CHC prevalence is highest. We developed a triplex high resolution melting assay for the simultaneous assessment of three genetic polymorphisms related to the response to treatment and development of advanced fibrosis in CHC: IL28B rs12979860, ABCB11 rs2287622, and RNF7 rs16851720. We validated the assay in clinical samples from 130 CHC patients treated with classical therapy...
August 28, 2017: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/28856277/efficacy-and-direct-costs-of-chronic-hepatitis-c-treatment-with-first-generation-ns3-4a-protease-inhibitors-in-a-real-life-population
#9
Anna Piekarska, Ewa Koślińska-Berkan, Kamila Wójcik, Anna Skubała, Maciej Jabłkowski, Zbigniew Deroń, Aleksandra Berkan-Kawińska
INTRODUCTION: Recent years have brought a significant advance in chronic hepatitis C (CHC) treatment that includes development of direct acting antivirals (DAA). Two of them, boceprevir (BOC) and telaprevir (TVR), were first approved for treatment of patients infected with CHC genotype 1 in combination with pegylated interferon (P) and ribavirin (R). Our aim was to evaluate the efficacy and direct costs of BOC/PR and TVR/PR in a real life population. MATERIAL AND METHODS: The study included adult patients qualified for the CHC Therapeutic Programme treated with TVR/PR or BOC/PR...
December 2016: Clin Exp Hepatol
https://www.readbyqxmd.com/read/28851700/model-based-projection-of-health-and-economic-effects-of-screening-for-hepatitis-c-in-canada
#10
William W L Wong, Aysegul Erman, Jordan J Feld, Murray Krahn
BACKGROUND: Because most hepatitis C virus (HCV) infections are asymptomatic and often unrecognized, screening for hepatitis C has been proposed as a plausible public health strategy. We examined the health and economic consequences of a selective one-time hepatitis C screening program for specific populations in the context of current treatment patterns. METHODS: We used a state-transition model to evaluate 2 general strategies: no screening, and screen and treat with direct-acting antiviral agents...
August 25, 2017: CMAJ Open
https://www.readbyqxmd.com/read/28851606/clinical-evaluation-of-a-newly-developed-automated-massively-parallel-sequencing-assay-for-hepatitis-c-virus-genotyping-and-detection-of-resistance-association-variants-comparison-with-a-line-probe-assay
#11
Narathon Manee, Nipa Thongbaiphet, Ekawat Pasomsub, Wasun Chantratita
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. Recently, HCV was classified into 6 major genotypes (GTs) and 67 subtypes (STs). Efficient genotyping has become an essential tool for prognosis and indicating suitable treatment, prior to starting therapy in all HCV-infected individuals. The widely used genotyping assays have limitation with regard to genotype accuracy. This study was a comparative evaluation of exact HCV genotyping in a newly developed automated-massively parallel sequencing (MPS) system, versus the established Line probe assay 2...
August 26, 2017: Journal of Virological Methods
https://www.readbyqxmd.com/read/28844170/non-healthcare-costs-of-hepatitis-c-a-systematic-review
#12
Natàlia Pascual-Argente, Jaume Puig-Junoy, Anna Llagostera-Punzano
There is an increasing interest in the indirect (or non-healthcare) costs of hepatitis C virus (HCV). Areas covered: Systematic review of original studies on the non-healthcare costs of HCV published in English or Spanish between January 2000 and March 2017. 19 studies addressing non-healthcare cost of HCV were included in the analysis. All studies but one contain treatments with monotherapy or dual therapy prior to the recent introduction of innovative and highly effective direct acting antivirals (DAAs). Five studies estimate the incremental non-healthcare cost of HCV with a control group, which is regarded as high-quality methodology...
September 8, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28836363/improving-pharmacotherapy-outcomes-in-patients-with-hepatitis-c-virus-infection-treated-with-direct-acting-antivirals-the-gruvic-project
#13
Esther Chamorro-de-Vega, Carmen Guadalupe Rodriguez-Gonzalez, Alvaro Gimenez-Manzorro, Ana de Lorenzo-Pinto, Irene Iglesias-Peinado, Ana Herranz, Maria Sanjurjo
BACKGROUND/OBJECTIVE: Pharmaceutical care is needed in hepatitis C virus (HCV)-infected patients treated with direct-acting antivirals (DAA). We describe the implementation of a comprehensive pharmaceutical care programme (CPCP) for HCV-infected patients treated with DAA in a tertiary-care hospital and provide data about health outcomes and costs. METHODS: Quasi-experimental study between 1 April 2015 and 30 June 2016. A group of hospital pharmacists collaborating on HCV infection implemented interventional measures for validation of drug prescriptions, detection of clinically relevant drug-drug interactions and adverse drug events (ADEs), and patient education...
August 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28836278/systematic-review-cost-effectiveness-of-direct-acting-antivirals-for-treatment-of-hepatitis-c-genotypes-2-6
#14
REVIEW
T He, M A Lopez-Olivo, C Hur, J Chhatwal
BACKGROUND: The availability of direct-acting antivirals (DAAs) has dramatically changed the landscape of hepatitis C virus (HCV) therapy; however, the cost and budget requirements for DAA treatment have been widely debated. AIMS: To systematically review published studies evaluating the cost-effectiveness of DAAs for HCV genotype 2-6 infections, and synthesise and re-evaluate results with updated drug prices. METHODS: We conducted a systematic search of various electronic databases, including Medline, EMBASE, Cochrane library and EconLit for cost-effectiveness studies published from 2011 to 2016...
August 24, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28834597/engaging-hepatitis-c-infected-patients-in-cost-effectiveness-analyses-a-literature-review
#15
REVIEW
T Joseph Mattingly, Eleanor M Perfetto, Sophia Johnson
OBJECTIVES: Cost-effectiveness analyses (CEA) of hepatitis C virus (HCV) treatment strategies have become common but few appear to include patient engagement or the patient perspective. The objectives of the current study were to (i) identify published HCV CEA studies that include patient input; and (ii) derive insights on patient-informed variable and outcome selection to build a framework for future economic analyses of HCV. METHODS: A literature search was conducted using SCOPUS, EMBASE, and PubMed from January 1 2012 to May 28, 2017...
August 23, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28833619/cost-effective-options-for-the-prevention-and-management-of-gastrointestinal-and-liver-disease-in-the-asia-pacific-region
#16
REVIEW
Ian C Roberts-Thomson, Thomas Lung
The Asia-Pacific region contains more than half of the world's population and is markedly heterogeneous in relation to income levels and the provision of public and private health services. For low-income countries, the major health priorities are child and maternal health. In contrast, priorities for high-income countries include vascular disease, cancer, diabetes, dementia and mental health disorders as well as chronic inflammatory disorders such as hepatitis B and hepatitis C. Cost-effectiveness analyses are methods for assessing the gains in health relative to the costs of different health interventions...
August 17, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28830254/modelling-the-fiscal-costs-and-benefits-of-alternative-treatment-strategies-in-the-united-kingdom-for-chronic-hepatitis-c
#17
Mark P Connolly, Nikos Kotsopoulos, Andrew Ustianowski
BACKGROUND: Hepatitis C (HCV) infection causes substantial direct health costs, but also impacts broader societal and governmental costs, such as tax revenue and social protection benefits. We investigated the broader fiscal costs and benefits of curative interventions for chronic Hepatitis C (CHC) that allow individuals to avoid long-term HCV attributed health conditions. METHODS: A prospective cohort model, assessing the long-term fiscal consequences of policy decisions, was developed for HCV infected individuals, following the generational accounting analytic framework that combines age-specific lifetime gross taxes paid and governmental transfers received (i...
August 23, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28830236/testing-many-treatments-within-a-single-protocol-over-10%C3%A2-years-at-mrc-clinical-trials-unit-at-ucl-multi-arm-multi-stage-platform-umbrella-and-basket-protocols
#18
Mahesh Kb Parmar, Fay H Cafferty, Matthew R Sydes, Babak Choodari-Oskooei, Ruth E Langley, Louise Brown, Patrick Pj Phillips, Melissa R Spears, Sam Rowley, Richard Kaplan, Nicholas D James, Timothy Maughan, Nicholas Paton, Patrick J Royston
BACKGROUND: There is real need to change how we do some of our clinical trials, as currently the testing and development process is too slow, too costly and too failure-prone - often we find that a new treatment is no better than the current standard. PURPOSE AND METHODS: Much of the focus on the development and testing pathway has been in improving the design of phase I and II trials. In this paper we present examples of new methods for improving the design of phase III trials (and the necessary lead up to them) as they are the most time-consuming and expensive part of the pathway...
August 1, 2017: Clinical Trials: Journal of the Society for Clinical Trials
https://www.readbyqxmd.com/read/28826994/effectiveness-and-cost-effectiveness-of-nationwide-campaigns-for-awareness-and-case-finding-of-hepatitis-c-targeted-at-people-who-inject-drugs-and-the-general-population-in-the-netherlands
#19
Charles W Helsper, Mart P Janssen, Gerrit A van Essen, Esther A Croes, Clary van der Veen, Ardine G de Wit, Niek J de Wit
BACKGROUND: Hepatitis C virus infection (HCV) is a serious, but underdiagnosed disease that can generally be treated successfully. Therefore, a nationwide HCV awareness campaign was implemented in the Netherlands targeting people who inject drugs (PWID) in addiction care ('PWID intervention') and high-risk groups in the general population ('public intervention'). The objective of this study is to assess the effectiveness and cost-effectiveness of the interventions used in this campaign...
September 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28820346/attitudes-and-potential-barriers-towards-hepatitis-c-treatment-in-patients-with-and-without-hiv-coinfection
#20
P R Allyn, S M O'Malley, J Ferguson, C H Tseng, K W Chew, D Bhattacharya
This study aimed to assess attitudes and potential barriers towards treatment in patients with hepatitis C virus (HCV) infection, comparing those with and without HIV coinfection. A cross-sectional survey of 82 HCV-infected adults with and without HIV was conducted in greater Los Angeles between November 2013 and July 2015. Overall, there were 53 (64.6%) with HIV coinfection, 20 (25.0%) with self-reported cirrhosis, and 22 (26.8%) with a history of prior HCV treatment. Of all, 93.2% wanted HCV treatment, but 45...
January 1, 2017: International Journal of STD & AIDS
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"